Skip to content

Exagen Inc. XGN Finance Lease Liabilities

Finance Lease Liabilities at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
$62.2M-6.5%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$8.6M-4.4%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$48.18M-15.2%

Other financials

Income statement

See full
Revenue$17.3M+11.7%
Gross profit$10.2M+11.9%
Operating income-$3.4M-1.5%
Net income-$4.0M-5.7%
EPS (diluted)-$0.17+15.0%

Balance sheet

See full
Cash & equivalents$21.7M+90.6%
Total debt$27.1M+15.8%
Total equity$14.4M+125%
Total assets$52.0M+28.9%

Cash flow

See full
Operating cash flow-$10.4M+2.4%
CapEx$228.0K+102%
Free cash flow-$10.6M+1.3%

Valuation

See full
Market cap$112.34M-26.5%
Enterprise value$117.78M-20.3%
P/S1.6×-1.0×

Profitability

See full
Gross margin58.3%-1.0pp
Operating margin-20.6%-2.9pp
Net margin-29.5%+2.5pp
FCF margin-27.5%

Returns & leverage

See full
Return on equity-193.6%+355pp
Debt / equity1.9×-1.8×
Current ratio3.5×+1.1×

Where this comes from

Reported directly by Exagen Inc. in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityNoncurrent.

The official record: Exagen Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exagen Inc.'s finance lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Exagen Inc.'s finance lease liabilities?
Exagen Inc. (XGN) reported finance lease liabilities of $1.79M in Q1 2026.
What is the long-term trend for Exagen Inc.'s finance lease liabilities?
Over 5 years (2020 to 2025), Exagen Inc.'s finance lease liabilities has grown at a 44.8% compound annual growth rate (CAGR), from $308K to $1.96M.
What does finance lease liabilities mean?
Present value of future payments on leases classified as finance leases under ASC 842 — treated similarly to debt on the balance sheet.